Pressroom
-
Alzheimer’s Drug Approved; USC Policy Experts Available to Discuss FDA Approval of Leqembi
For the first time in two decades, an Alzheimer’s drug has received full Food and Drug Administration (FDA) approval. USC Schaeffer Center experts are available to discuss this milestone and the challenges ahead.
Categorized in -
Overpayments to Medicare Advantage Plans Could Exceed $75 Billion in 2023, USC Schaeffer Center Research Finds
Overpayments to Medicare Advantage plans now exceed 20% annually, underscoring the urgent need for reform.
Categorized in -
Comparing Doctors to Peers Doesn’t Make Them Hate Their Jobs and May Improve Quality of Care
Researchers found that behavioral interventions aimed at improving performance can be designed to protect clinician job satisfaction and improve quality of care.
Categorized in -
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Categorized in -
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Categorized in -
Schaeffer Research Director Testifies at Congressional Hearing on Biomedical Innovation and Patient Access
Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.
-
Medicare Coverage of Weight Loss Drugs Could Significantly Reduce Costs
USC Schaeffer white paper finds that increasing access to obesity treatments would help save lives and reduce healthcare costs.
Categorized in -
New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs
The researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.
Categorized in -
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”
-
Prominent Health Executive Tom Priselac Named Vice Chair of Schaeffer Center Advisory Board
Priselac, who is CEO and president of Cedars-Sinai, has served on the board since its inception in 2011.